Xencor, Inc. (NASDAQ:XNCR) Stock Has Average Price Target of $42.22 According to Analysts

Xencor, Inc. (NASDAQ:XNCR) has earned an average rating of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $42.22.

A number of analysts recently issued reports on the stock. Raymond James Financial increased their price target on shares of Xencor from $40.00 to $46.00 and gave the stock a “strong-buy” rating in a report on Tuesday, September 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a report on Monday, September 21st. Royal Bank Of Canada increased their target price on shares of Xencor from $20.00 to $43.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 27th. Wells Fargo & Company raised their target price on Xencor from $30.00 to $44.00 and gave the company an “overweight” rating in a research report on Tuesday, October 27th. Finally, Wall Street Zen upgraded Xencor from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th.

Insider Transactions at Xencor

In related news, Director Richard Ranieri sold 81,252 shares of the business’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $39.25, for a total value of $3,189,141.00. Following the completion of the sale, the director owned 18,514 shares of the company’s stock, valued at approximately $726,674.50. The trade was a 81.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 5.08% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of XNCR. Steward Partners Investment Advisory LLC purchased a new position in Xencor in the 3rd quarter valued at about $25,000. Integrated Wealth Concepts LLC purchased a new stake in Xencor during the 2nd quarter worth approximately $30,000. Bessemer Group Inc. raised its holdings in shares of Xencor by 18.7% during the third quarter. Bessemer Group Inc. now owns 1,791 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 282 shares during the last quarter. Allworth Financial LP acquired a new position in Xencor in the 2nd quarter valued at $55,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Xencor in the third quarter valued at about $95,000.

Xencor Price Performance

NASDAQ:XNCR traded down $1.04 during trading hours on Friday, reaching $37.09. The company had a trading volume of 958,135 shares, compared to its average volume of 1,821,041. Xencor has a 1-year low of $10.38 and a 1-year high of $40.60. The business’s 50 day moving average price is $27.34 and its 200-day moving average price is $18.10. The firm has a market cap of $2.78 billion, a PE ratio of -23.33 and a beta of 0.78.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.83. The business had revenue of $116.52 million for the quarter, compared to analysts’ expectations of $63.00 million. Xencor had a negative net margin of 58.79% and a negative return on equity of 21.28%. The business’s revenue was up 453.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.08) EPS. On average, analysts expect that Xencor will post -2.61 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.